P2Y12 Polymorphisms and the Risk of Adverse Clinical Events in Patients Treated with Clopidogrel: A Meta-Analysis

Kun Zhao; Ming Yang; Yanxia Lu; Shusen Sun; Wei Li; Xingang Li; Zhigang Zhao

doi:10.1055/a-0622-8110

Drug Research, Inhaltsverzeichnis

Drug Res (Stuttg) 2019; 69(01): 23-31
DOI: 10.1055/a-0622-8110

Original Article

P2Y12 Polymorphisms and the Risk of Adverse Clinical Events in Patients Treated with Clopidogrel: A Meta-Analysis

Kun Zhao^*

¹Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China

²Department of Pharmacy, Beijing Friendship Hospital Pinggu Campus, Capital Medical University, Beijing, People's Republic of China

,

Ming Yang^*

³Department of Anesthesiology, Tianjin Eye Hospital, Tianjin, People's Republic of China

,

Yanxia Lu

⁴Department of Pharmacy, The General Hospital of the Chinese People's Armed Police Forces, Beijing, People's Republic of China

,

Shusen Sun

⁵College of Pharmacy and Health Sciences, Western New England University, Springfield, Massachusetts, United States of America

,

Wei Li

⁶Monogenic Disease Research Center for Neurological Disorders, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China

,

Xingang Li

¹Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China

⁶Monogenic Disease Research Center for Neurological Disorders, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China

,

Zhigang Zhao

¹Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China

⁶Monogenic Disease Research Center for Neurological Disorders, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China

› Institutsangaben

Abstract

Background and study aim Some studies have reported an association between P2Y12 gene polymorphisms and clopidogrel adverse outcomes with inconsistent results. We aimed to explore the relationship between P2Y12 polymorphisms and the risk of adverse clinical events in patients treated with clopidogrel through a meta-analysis.

Methods A systematic search of PubMed, Web of Science and the Cochrane Library was conducted. Retrieved articles were comprehensively reviewed and eligible studies were included, and the relevant data was extracted for this meta-analysis. All statistical tests were performed by the Review Manager 5.3 software.

Results A total of 14 studies involving 8,698 patients were included. In the Han Chinese population, ischemic events were associated with P2Y12 T744C polymorphism in the CC vs TT+CT genetic model (OR=3.32, 95%CI=1.62-6.82, P=0.001), and the events were associated with P2Y12 C34T polymorphism in the TT+TC vs CC genetic model (OR=1.70, 95%CI=1.22-2.36, P=0.002). However, ischemic events were not related to P2Y12 G52T polymorphism (TT+TG vs GG: OR=1.13, 95%CI=0.76-1.68, P=0.56; TT vs GG+TG: OR=2.02, 95%CI=0.65-6.28, P=0.22). The associations between the P2Y12 polymorphism and ischemic events were not significant in T744C, G52T and C34T genotype for another subgroup of the Caucasian population (P>0.05). Only two studies referring to bleeding events were included in this analysis of C34T polymorphism, and no significant association was found (TT+TC vs CC: OR=1.07, 95%CI=0.37-3.15, P=0.90).

Conclusions In the Caucasian population, P2Y12 gene polymorphisms are not associated with clinical events. However, in the Chinese Han population, P2Y12 T744C and C34T polymorphisms are significantly associated with adverse clinical events.

Key words

Clopidogrel - adverse clinical events - P2Y12 polymorphism - meta-analysis

Volltext

Referenzen

References
1 Tang M, Mukundan M, Yang J. et al. Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther 2006; 319: 1467-1476
2 Wright RS, Anderson JL, Adams CD. et al. 2011; ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123: 2022-2060
3 Qiu LN, Sun Y, Wang L. et al. Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel. Eur J Pharmacol 2015; 747: 29-35
4 Yang J, Wang X, Peng L. et al. CYP2C19 LOF alleles confer no risk for HTPR but higher risk for recurrent ischemic events in clopidogrel treated elderly ACS patients. Int J Cardiol 2015; 189: 225-227
5 Bundhun PK, Qin T, Chen MH. Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: A systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 2015; 15: 118
6 Campo G, Fileti L, Valgimigli M. et al. Poor response to clopidogrel: Current and future options for its management. J Thromb Thrombolysis 2010; 30: 319-331
7 Fontana P, Dupont A, Gandrille S. et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003; 108: 989-995
8 Li XQ, Ma N, Li XG. et al. Association of PON1, P2Y12 and COX1 with Recurrent Ischemic Events in Patients with Extracranial or Intracranial Stenting. PLoS One 2016; 11: e0148891
9 Sun B, Li J, Dong M. et al. Diversity of platelet function and genetic polymorphism in clopidogrel-treated Chinese patients. Genet Mol Res 2015; 14: 1434-1442
10 Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603-605
11 Su J, Xu J, Li X. et al. ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: A meta-analysis. PLoS One 2012; 7: e46366
12 Serbin MA, Guzauskas GF, Veenstra DL. Clopidogrel-Proton Pump Inhibitor Drug-Drug Interaction and Risk of Adverse Clinical Outcomes Among PCI-Treated ACS Patients: A Meta-analysis. J Manag Care Spec Pharm 2016; 22: 939-947
13 Wen Y, Huang Z, Zhang X. et al. Correlation between PON1 gene polymorphisms and breast cancer risk: A Meta-analysis. Int J. Clin Exp Med 2015; 8: 20343-20348
14 Ziegler S, Schillinger M, Funk M. et al. Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. Stroke 2005; 36: 1394-1399
15 Wu H, Qian J, Xu J. et al. Effects of CYP2C19 variant alleles on postclopidogrel platelet reactivity and clinical outcomes in an actual clinical setting in China. Pharmacogenet Genomics 2012; 22: 887-890
16 Liang ZY, Han YL, Zhang XL. et al. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: Outcomes in patients with acute coronary syndrome after drug-eluting stent implantation. EuroIntervention 2013; 9: 316-327
17 Yi X, Wang Y, Lin J et al. Interaction of CYP2C19, P2Y12, and GPIIIa Variants Associates With Efficacy of Clopidogrel and Adverse Events on Patients With Ischemic Stroke. Clin Appl Thromb Hemost 2016
18 Bouman HJ, van Werkum JW, Rudez G. et al. The relevance of P2Y(12)-receptor gene variation for the outcome of clopidogrel-treated patients undergoing elective coronary stent implantation: A clinical follow-up. Thromb Haemost 2012; 107: 189-191
19 Siasos G, Oikonomou E, Vavuranakis M. et al. Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance. Cardiology 2017; 137: 104-113
20 Smith SM, Judge HM, Peters G. et al. Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy. Platelets 2006; 17: 250-258
21 Li XJ, Chen XM. Association between clopidogrel resistance and polymorphism of platelet adenosine diphosphate receptor in patients with coronary atherosclerotic disease. Zhejiang Da Xue Xue Bao Yi Xue Ban 2014; 43: 333-338
22 Lin YJ, Li JW, Zhang MJ. et al. The association between CYP2C19 genotype and of in-stent restenosis among patients with vertebral artery stent treatment. CNS Neurosci Ther 2014; 20: 125-130
23 Malek LA, Kisiel B, Spiewak M. et al. Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel. Circ J 2008; 72: 1165-1169
24 Zhang JH, Wang J, Tang XF. et al. Effect of platelet receptor gene polymorphisms on outcomes in ST-elevation myocardial infarction patients after percutaneous coronary intervention. Platelets 2016; 27: 75-79
25 Tang XF, Zhang JH, Wang J. et al. Effects of coexisting polymorphisms of CYP2C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention. Chin Med J (Engl) 2013; 126: 1069-1075
26 Sen HM, Silan F, Silan C. et al. Effects of CYP2C19 and P2Y12 Gene Polymorphisms on Clinical Results of Patients Using Clopidogrel after Acute Ischemic Cerebrovascular Disease. Balkan J Med Genet 2014; 17: 37-41
27 Simon T, Verstuyft C, Mary-Krause M. et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-375
28 Siasos G, Kioufis S, Oikonomou E. et al. Impact of C34T P2Y12 ADP receptor polymorphism and smoking status on cardiovascular outcome in coronary artery disease patients receiving clopidogrel. Int J Cardiol 2016; 210: 161-163
29 Rudez G, Pons D, Leebeek F. et al. Platelet receptor P2RY12 haplotypes predict restenosis after percutaneous coronary interventions. Hum Mutat 2008; 29: 375-380
30 Viviani Anselmi C, Briguori C, Roncarati R. et al. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. JACC Cardiovasc Interv 2013; 6: 1166-1175
31 Li M, Wang H, Xuan L. et al. Associations between P2RY12 gene polymorphisms and risks of clopidogrel resistance and adverse cardiovascular events after PCI in patients with acute coronary syndrome. Medicine (Baltimore) 2017; 96: e6553
32 Yang HH, Chen Y, Gao CY. Associations of P2Y12R gene polymorphisms with susceptibility to coronary heart disease and clinical efficacy of antiplatelet treatment with clopidogrel. Cardiovasc Ther 2016; 34: 460-467
33 Ou W, He Y, Li A. et al. Genotype Frequencies of CYP2C19, P2Y12 and GPIIIa Polymorphisms in Coronary Heart Disease Patients of Han Ethnicity, and Their Impact on Clopidogrel Responsiveness. Int Heart J 2016; 57: 586-592
34 Wang X, Lai Y, Luo Y. et al. Relationship between clopidogrel-related polymorphisms and variable platelet reactivity at 1 year: A cohort study from Han Chinese. J Res Med Sci 2016; 21: 111
35 Li XG, Ma N, Wang B. et al. The impact of P2Y12 promoter DNA methylation on the recurrence of ischemic events in Chinese patients with ischemic cerebrovascular disease. Sci Rep 2016; 6: 34570
36 Shuldiner AR, O'Connell JR, Bliden KP. et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302: 849-857
37 Martinelli N, Trabetti E, Pinotti M. et al. Combined effect of hemostatic gene polymorphisms and the risk of myocardial infarction in patients with advanced coronary atherosclerosis. PLoS One 2008; 3: e1523
38 Storey RF. Biology and pharmacology of the platelet P2Y12 receptor. Curr Pharm Des 2006; 12: 1255-1259
39 Haynes SE, Hollopeter G, Yang G. et al. The P2Y12 receptor regulates microglial activation by extracellular nucleotides. Nat Neurosci 2006; 9: 1512-1519
40 Sionova M, Blasko P, Jirous S. et al. Association of polymorphisms of platelet receptors GPIa (807C>T), GPVI (13254 T>C), and P2Y12 (34C>T and H1/H2 haplotype) with increased risk of periprocedural bleeding in patients undergoing coronary angiography/percutaneous coronary intervention. Postepy Kardiol Interwencyjnej 2017; 13: 202-209

Zusatzmaterial

Supporting Information